JP2015078230A5 - - Google Patents

Download PDF

Info

Publication number
JP2015078230A5
JP2015078230A5 JP2015006124A JP2015006124A JP2015078230A5 JP 2015078230 A5 JP2015078230 A5 JP 2015078230A5 JP 2015006124 A JP2015006124 A JP 2015006124A JP 2015006124 A JP2015006124 A JP 2015006124A JP 2015078230 A5 JP2015078230 A5 JP 2015078230A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
following formula
acceptable salt
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015006124A
Other languages
English (en)
Japanese (ja)
Other versions
JP5963894B2 (ja
JP2015078230A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015078230A publication Critical patent/JP2015078230A/ja
Publication of JP2015078230A5 publication Critical patent/JP2015078230A5/ja
Application granted granted Critical
Publication of JP5963894B2 publication Critical patent/JP5963894B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2015006124A 1999-12-03 2015-01-15 ホスホネート化合物 Expired - Lifetime JP5963894B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16881399P 1999-12-03 1999-12-03
US60/168,813 1999-12-03
US20571900P 2000-05-19 2000-05-19
US60/205,719 2000-05-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011153911A Division JP2011246475A (ja) 1999-12-03 2011-07-12 ホスホネート化合物

Publications (3)

Publication Number Publication Date
JP2015078230A JP2015078230A (ja) 2015-04-23
JP2015078230A5 true JP2015078230A5 (enExample) 2015-12-24
JP5963894B2 JP5963894B2 (ja) 2016-08-03

Family

ID=26864475

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2001541459A Expired - Lifetime JP4993649B2 (ja) 1999-12-03 2000-12-04 ホスホネート化合物
JP2011153911A Withdrawn JP2011246475A (ja) 1999-12-03 2011-07-12 ホスホネート化合物
JP2014002881A Expired - Lifetime JP5963787B2 (ja) 1999-12-03 2014-01-10 ホスホネート化合物
JP2015006124A Expired - Lifetime JP5963894B2 (ja) 1999-12-03 2015-01-15 ホスホネート化合物

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2001541459A Expired - Lifetime JP4993649B2 (ja) 1999-12-03 2000-12-04 ホスホネート化合物
JP2011153911A Withdrawn JP2011246475A (ja) 1999-12-03 2011-07-12 ホスホネート化合物
JP2014002881A Expired - Lifetime JP5963787B2 (ja) 1999-12-03 2014-01-10 ホスホネート化合物

Country Status (18)

Country Link
US (14) US6716825B2 (enExample)
EP (1) EP1233770B1 (enExample)
JP (4) JP4993649B2 (enExample)
KR (1) KR20020073342A (enExample)
CN (1) CN1414854B (enExample)
AT (1) ATE385797T1 (enExample)
AU (3) AU785355B2 (enExample)
BR (1) BR0016058A (enExample)
CA (2) CA2393410C (enExample)
CY (1) CY1107927T1 (enExample)
DE (1) DE60038038T2 (enExample)
DK (2) DK1233770T3 (enExample)
ES (2) ES2300281T3 (enExample)
HK (1) HK1050627B (enExample)
MX (1) MXPA02005490A (enExample)
PT (2) PT1233770E (enExample)
RU (1) RU2258707C2 (enExample)
WO (1) WO2001039724A2 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
DK1233770T3 (da) * 1999-12-03 2008-06-16 Univ California At San Diego Phosphonatforbindelser
WO2002102813A1 (en) * 2001-06-20 2002-12-27 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids for treatment of diabetes
JP4220382B2 (ja) * 2001-07-16 2009-02-04 ユニヴェルシテ・パリ・１３ 新しいビスホスホナート誘導体、その製造法及び使用
FR2837490B1 (fr) * 2002-03-21 2009-04-17 Univ Paris 13 Nouveaux derives de bisphosphonates, leurs preparations et utilisations
US7488496B2 (en) 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
CA2495886C (en) * 2002-03-06 2011-05-03 Lifizz, Inc. Effervescent compositions comprising bisphosphonates and methods related thereto
MXPA04010528A (es) * 2002-04-26 2005-05-27 Gilead Sciences Inc Inhibidores de transcriptasa inversa no nucleosidos.
RU2309747C2 (ru) * 2002-09-18 2007-11-10 Михаил Владимирович Кутушов Применение 2-хлорэтилфосфоновой кислоты и ее солей в качестве противоопухолевого средства
AU2003901813A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Pharmaceutical derivatives
EP2359833A1 (en) 2003-04-25 2011-08-24 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
JP2006524710A (ja) 2003-04-25 2006-11-02 ギリアード サイエンシーズ， インコーポレイテッド キナーゼインヒビターホスホネート抱合体
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
CA2543294A1 (en) 2003-10-24 2005-05-26 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
WO2005056019A1 (ja) * 2003-12-12 2005-06-23 Astellas Pharma Inc. 悪性黒色腫治療剤
NZ547907A (en) 2003-12-22 2010-07-30 Gilead Sciences Inc 4'-Substituted carbovir-and abacavir-derivatives as well as related compounds with HIV and HCV antiviral activity
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
WO2006076015A2 (en) * 2004-04-30 2006-07-20 The Regents Of The University Of California 1-[2-(phosphonomethoxy)ethyl]-cytosine and analogs thereof
CA2574514A1 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Phosphonate analogs of hiv inhibitor compounds
WO2006055525A2 (en) * 2004-11-15 2006-05-26 Ceptyr, Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
EP1831235B1 (en) 2004-12-16 2013-02-20 The Regents of The University of California Lung-targeted drugs
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US20060219637A1 (en) * 2005-03-29 2006-10-05 Killeen Kevin P Devices, systems and methods for liquid chromatography
WO2006130217A2 (en) * 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates
EP1868628B1 (en) * 2005-04-08 2014-06-11 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
WO2006110656A2 (en) * 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of viral infections and other medical disorders
EP1879657A2 (en) * 2005-04-25 2008-01-23 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
US7914810B2 (en) * 2005-05-06 2011-03-29 Synthes Usa, Llc Methods for the in situ treatment of bone cancer
US8114843B2 (en) * 2005-11-18 2012-02-14 The Regents Of The University Of California Photoreactive regulator of protein function and methods of use thereof
US7749983B2 (en) 2006-05-03 2010-07-06 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
ES2609095T3 (es) * 2007-04-27 2017-04-18 Chimerix, Inc. Métodos de reducción de la nefrotoxicidad en sujetos a quienes se administra nucleósido
CN102137676A (zh) * 2007-12-27 2011-07-27 伊皮芬尼生物科学公司 抗病毒化合物
EP3085377A1 (en) 2008-01-25 2016-10-26 Chimerix, Inc. Methods of treating viral infections
NZ590075A (en) 2008-07-08 2012-12-21 Gilead Sciences Inc citrate, malonate and succinate salts of the HIV inhibitor ethyl N-[(S)({ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy} methyl)phenoxyphosphinoyl]-L-alaninate
US8628812B2 (en) 2008-12-30 2014-01-14 Pepsico, Inc. Preservative system for acidic beverages based on sequestrants
EP2270021A1 (en) * 2009-06-18 2011-01-05 Centre National de la Recherche Scientifique Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability
WO2011005510A2 (en) * 2009-06-22 2011-01-13 Cerapedics, Inc. Peptide conjugates and uses thereof
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
CA2770282A1 (en) 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
JP5748759B2 (ja) * 2009-10-02 2015-07-15 ストレイトマーク・ホールディング・アーゲー アミノヒドロキシジホスホン酸の製造方法
EP2534150B1 (en) 2010-02-12 2017-04-05 Chimerix, Inc. Methods of treating viral infection
CN102939291B (zh) 2010-04-14 2016-09-07 加利福尼亚大学董事会 用于病毒感染治疗的具有降低的毒性的膦酸酯
CA2797601A1 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
RU2015141024A (ru) * 2010-08-31 2018-12-26 Чимерикс, Инк. Производные эфиров фосфоновых кислот и способы их синтеза
AU2015201895B2 (en) * 2010-08-31 2016-11-17 Emergent Biodefence Operations Lansing Llc Phosphonate ester derivatives and methods of synthesis thereof
US8884027B2 (en) 2010-10-22 2014-11-11 University Of Rochester Melampomagnolide B derivatives as antileukemic and cytotoxic agents
WO2013033450A2 (en) * 2011-08-31 2013-03-07 Mallinckrodt Llc Remote assembly of targeted nanoparticles using h-phosphonate-ene/-yne hydrophosphonylation reactions
EP2794624B1 (en) 2011-12-22 2019-05-15 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
WO2014035945A1 (en) * 2012-08-28 2014-03-06 Glaxosmithkline Llc Pharmaceutical compositions
CN107056838A (zh) 2013-03-15 2017-08-18 加利福尼亚大学董事会 无环核苷膦酸二酯
IL302520A (en) 2013-11-15 2023-07-01 Chimerix Inc Morphic forms of hexadecyloxypropyl-phosphonate esters
WO2015123352A1 (en) 2014-02-13 2015-08-20 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2015137983A1 (en) 2014-03-14 2015-09-17 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
KR102589658B1 (ko) 2014-09-15 2023-10-13 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뉴클레오타이드 유사체
US10160778B2 (en) 2014-10-27 2018-12-25 Concert Pharmaceuticals, Inc. Pyrimidine phosphonic acid esters
CN107427530B (zh) 2015-03-06 2020-09-08 阿堤亚制药公司 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸
CN108135863B (zh) * 2015-04-27 2021-07-27 特拉维夫医疗中心医学研究基础设施和保健服务基金会 用于治疗炎性和过度增殖性病况的egr1靶向分子
WO2017048956A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Nucleotide analogs
WO2017048252A1 (en) 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
US20170368082A1 (en) 2016-06-28 2017-12-28 Chimerix, Inc. Formulations of brincidofovir
RU2628456C1 (ru) * 2016-06-29 2017-08-17 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Новые пиримидиновые ингибиторы репликации аденовируса человека
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
CN109689672B (zh) 2016-09-07 2023-05-30 阿堤亚制药公司 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
RU2670204C1 (ru) * 2017-12-01 2018-10-19 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Производные 2-тиоурацила, обладающие противоаденовирусной активностью
EP3730503A4 (en) * 2017-12-21 2021-05-05 Shenzhen TargetRx, Inc. ANTIVIRAL NUCLEOSIDIC REVERSE TRANSCRIPTASE INHIBITORS
RU2020126177A (ru) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. Ацетальные соединения и их терапевтическое применение
CA3152013A1 (en) 2019-08-22 2021-02-25 Emory University Nucleoside prodrugs and uses related thereto
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CA3188373A1 (en) 2020-08-24 2022-03-03 Scott E. Lazerwith Phospholipid compounds and uses thereof
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
CN117285566A (zh) * 2022-06-24 2023-12-26 润佳（苏州）医药科技有限公司 一种膦酸酯类化合物及其医药用途
IL318465A (en) 2022-07-21 2025-03-01 Antiva Biosciences Inc Compositions and dosage forms for the treatment of HPV infection and HPV-induced neoplasia

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1944530A (en) * 1929-04-08 1934-01-23 Ig Farbenindustrie Ag Phosphoric acid esters
DE2009341C3 (de) 1970-02-27 1979-06-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen 3-Octadecyloxy-propanol-(l)-phosphorsäure-monocholinester und Verfahren zu dessen Herstellung
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
FR2586685B1 (fr) * 1985-09-03 1987-12-11 Protex Manuf Prod Chimiq Procede de preparation de nouveaux agents dispersants cationiques
SU1594953A1 (ru) * 1988-12-30 1991-05-15 Институт Молекулярной Биологии Им.В.А.Энгельгардта Аммонийна соль 9-(4-гидрофосфорил-2-оксабутил)гуанина, обладающа избирательной активностью против вируса простого герпеса
FI83421C (fi) * 1989-06-21 1991-07-10 Huhtamaeki Oy Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat.
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
ATE167679T1 (de) * 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
EP0477454A1 (en) * 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
US5672697A (en) * 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
JPH05339280A (ja) * 1991-04-26 1993-12-21 Japan Tobacco Inc （ｎ−二環置換）アミノメチレンビスフォスフォン酸誘導体
JP3341303B2 (ja) * 1991-07-11 2002-11-05 東レ株式会社 メチレンジホスホン酸誘導体、その製造方法およびその医薬用途
US5879700A (en) 1991-10-15 1999-03-09 Hostetler; Karl Y. Nucleoside analogue phosphates for topical use
WO1994001442A1 (fr) 1992-07-10 1994-01-20 Toray Industries, Inc. Derive de methanediphosphonate, sa production, et son usage pharmaceutique
JP3580377B2 (ja) * 1993-06-29 2004-10-20 三菱化学株式会社 ホスホナートヌクレオチドエステル誘導体
DE69426904T2 (de) 1993-06-29 2001-10-11 Mitsubishi Chemical Corp., Tokio/Tokyo Phosphonat-Nukleotid Ester-Derivate
US5627185A (en) * 1994-11-23 1997-05-06 Gosselin; Gilles Acyclovir derivatives as antiviral agents
CH690163A5 (fr) 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
WO1998026749A1 (en) * 1996-12-19 1998-06-25 Kao Corporation Coating composition for teeth
US6686462B2 (en) * 1997-02-28 2004-02-03 The Regents Of The University Of California Antiviral compounds and methods of administration
WO1999008685A1 (en) * 1997-08-18 1999-02-25 Queen's University At Kingston Phosphono-carboxylate compounds for treating amyloidosis
FR2781228B1 (fr) * 1998-07-16 2000-09-29 Pf Medicament Phosphonates insatures derives d'indole
DK1233770T3 (da) * 1999-12-03 2008-06-16 Univ California At San Diego Phosphonatforbindelser

Similar Documents

Publication Publication Date Title
JP2015078230A5 (enExample)
JP2014221779A5 (enExample)
JP2014507446A5 (enExample)
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
JP2013032389A5 (enExample)
JP2017105793A5 (enExample)
JP2013014622A5 (enExample)
JP2016518337A5 (enExample)
FI3256218T3 (fi) Kdm1a-estäjät sairauksien hoidossa
JP2017509667A5 (enExample)
JP2013518107A5 (enExample)
MD20140073A2 (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
JP2015504081A5 (enExample)
JP2017517565A5 (enExample)
JP2014218522A5 (enExample)
MX394588B (es) Composición farmacéutica.
JP2011527299A5 (enExample)
PH12015501945B1 (en) Formulations of organic compounds
PH12018500377A1 (en) Novel annelated benzamides
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
RU2017141536A (ru) Замещенные производные индол-5-ола и их терапевтические применения
JP2016532632A5 (enExample)
EP2871187A4 (en) A NEW CONNECTION OR PHARMACEUTICALALLY SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS AN ACTIVE SUBSTANCE
EA201692298A1 (ru) Производные карбоксамидов